Alpha Tau Medical’s (DRTS) “Buy” Rating Reaffirmed at HC Wainwright

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 66.02% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Barclays assumed coverage on Alpha Tau Medical in a research note on Thursday, May 28th. They issued an “overweight” rating and a $15.00 price objective for the company. Zacks Research upgraded Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 17th. LADENBURG THALM/SH SH increased their price target on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a report on Tuesday, May 19th. Finally, Citigroup upped their price objective on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.20.

Alpha Tau Medical Stock Down 16.6%

NASDAQ:DRTS traded down $1.80 during trading hours on Tuesday, hitting $9.04. 1,965,873 shares of the stock traded hands, compared to its average volume of 1,028,149. The firm has a 50 day moving average price of $8.38 and a 200 day moving average price of $6.83. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical has a fifty-two week low of $2.81 and a fifty-two week high of $11.62. The firm has a market cap of $816.13 million, a price-to-earnings ratio of -13.78 and a beta of 1.19.

Alpha Tau Medical (NASDAQ:DRTS) last issued its earnings results on Monday, May 18th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities research analysts anticipate that Alpha Tau Medical will post -0.6 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of DRTS. Apella Capital LLC acquired a new stake in shares of Alpha Tau Medical in the 4th quarter valued at $1,892,000. Levin Capital Strategies L.P. increased its position in Alpha Tau Medical by 6.3% during the third quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock worth $923,000 after buying an additional 12,200 shares during the last quarter. Daytona Street Capital LLC bought a new position in Alpha Tau Medical during the fourth quarter valued at about $749,000. Mariner LLC lifted its position in shares of Alpha Tau Medical by 1.6% in the fourth quarter. Mariner LLC now owns 125,165 shares of the company’s stock worth $620,000 after buying an additional 1,915 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock worth $534,000 after acquiring an additional 70,081 shares in the last quarter. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.